Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias

被引:28
作者
Barrett, A. J. [1 ]
Rezvani, K. [1 ]
机构
[1] NHLBI, Hematol Branch, Stem Cell Allotransplantat Sect, Clin Res Ctr,NIH, Bethesda, MD 20892 USA
关键词
clinical trials; myeloid leukaemia; peptide; vaccines;
D O I
10.1111/j.1365-2249.2007.03383.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The graft-versus-leukaemia (GVL) effect following allogeneic stem cell transplantation is clear evidence that T lymphocytes can control and eliminate myeloid leukaemias. The successful identification of a range of leukaemia specific antigens (LSA) in recent years has stimulated efforts to induce leukaemia specific T cell responses to these antigens with peptide vaccines. An ideal LSA should be restricted in its expression to leukaemia including progenitor cells, intrinsically connected with the leukaemic phenotype, and capable of inducing strong cytotoxic T cell responses to the leukaemia. Peptides from three well-characterized LSA, the breakpoint cluster region-abelson (BCR-ABL) fusion protein of chronic myelogenous leukaemia, proteinase-3 and Wilms tumour 1 protein, serve as the basis for several clinical trials using peptide and adjuvants to treat patients with a variety of myeloid malignancies. Preliminary results from these studies indicate that these peptides induce immune responses which can translate into clinical responses which include complete remissions from leukaemia. These promising early results point the way to optimizing the administration of peptide vaccines and suggest ways of combining vaccination with allogeneic stem cell transplantation to boost GVL effects.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 113 条
[1]   Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation [J].
Alpdogan, O ;
Eng, JM ;
Muriglan, SJ ;
Willis, LM ;
Hubbard, VM ;
Tjoe, KH ;
Terwey, T ;
Kochman, A ;
van den Brink, MRM .
BLOOD, 2005, 105 (02) :865-873
[2]   Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity [J].
Amrolia, PJ ;
Reid, SD ;
Gao, LQ ;
Schultheis, B ;
Dotti, G ;
Brenner, MK ;
Melo, JV ;
Goldman, JM ;
Stauss, HJ .
BLOOD, 2003, 101 (03) :1007-1014
[3]  
ANTIN JH, 1993, BLOOD, V82, P2273
[4]   Antibodies to neutrophil elastase: A study in patients with vasculitis [J].
Apenberg, S ;
Andrassy, K ;
Worner, I ;
Hansch, GM ;
Roland, J ;
Morcos, M ;
Ritz, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (02) :178-185
[5]   Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes [J].
Arai, J ;
Yasukawa, M ;
Ohminami, H ;
Kakimoto, M ;
Hasegawa, A ;
Fujita, S .
BLOOD, 2001, 97 (09) :2903-2907
[6]   Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity [J].
Bae, J ;
Martinson, JA ;
Klingemann, HG .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :7043-7052
[7]  
BALLIEUX BEPB, 1995, CLIN EXP IMMUNOL, V100, P186
[8]   Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen can function as targets for leukemia-reactive CTL [J].
Bellantuono, I ;
Gao, LQ ;
Parry, S ;
Marley, S ;
Dazzi, F ;
Apperley, J ;
Goldman, JM ;
Stauss, HJ .
BLOOD, 2002, 100 (10) :3835-3837
[9]   High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome [J].
Bergmann, L ;
Miething, C ;
Maurer, U ;
Brieger, J ;
Karakas, T ;
Weidmann, E ;
Hoelzer, D .
BLOOD, 1997, 90 (03) :1217-1225
[10]   Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection [J].
Betts, MR ;
Ambrozak, DR ;
Douek, DC ;
Bonhoeffer, S ;
Brenchley, JM ;
Casazza, JP ;
Koup, RA ;
Picker, LJ .
JOURNAL OF VIROLOGY, 2001, 75 (24) :11983-11991